[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

Spinal Muscular Atrophy (SMA) Drugs Market - Global Outlook and Forecast 2021-2027

March 2021 | 94 pages | ID: S502E1638292EN
Market Monitor Global

US$ 3,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report contains market size and forecasts of Spinal Muscular Atrophy (SMA) Drugs in Global, including the following market information:

Global Spinal Muscular Atrophy (SMA) Drugs Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Spinal Muscular Atrophy (SMA) Drugs market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Spinal Muscular Atrophy (SMA) Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Spinal Muscular Atrophy (SMA) Drugs Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Spinal Muscular Atrophy (SMA) Drugs Market Segment Percentages, By Type, 2020 (%)
  • Oral Medicine
  • Injection Medicine
China Spinal Muscular Atrophy (SMA) Drugs Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Spinal Muscular Atrophy (SMA) Drugs Market Segment Percentages, By Application, 2020 (%)
  • Baby
  • Child
  • Adult
Global Spinal Muscular Atrophy (SMA) Drugs Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Spinal Muscular Atrophy (SMA) Drugs Market Segment Percentages, By Region and Country, 2020 (%)
  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Nordic Countries
    • Benelux
    • Rest of Europe
  • Asia
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Rest of Asia
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • Turkey
    • Israel
    • Saudi Arabia
    • UAE
    • Rest of Middle East & Africa
Competitor Analysis

The report also provides analysis of leading market participants including:

Total Spinal Muscular Atrophy (SMA) Drugs Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Spinal Muscular Atrophy (SMA) Drugs Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:
  • Biogen
  • Novartis
  • Genentech
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Spinal Muscular Atrophy (SMA) Drugs Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Spinal Muscular Atrophy (SMA) Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL SPINAL MUSCULAR ATROPHY (SMA) DRUGS OVERALL MARKET SIZE

2.1 Global Spinal Muscular Atrophy (SMA) Drugs Market Size: 2021 VS 2027
2.2 Global Spinal Muscular Atrophy (SMA) Drugs Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Spinal Muscular Atrophy (SMA) Drugs Players in Global Market
3.2 Top Global Spinal Muscular Atrophy (SMA) Drugs Companies Ranked by Revenue
3.3 Global Spinal Muscular Atrophy (SMA) Drugs Revenue by Companies
3.4 Top 3 and Top 5 Spinal Muscular Atrophy (SMA) Drugs Companies in Global Market, by Revenue in 2020
3.5 Global Companies Spinal Muscular Atrophy (SMA) Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Spinal Muscular Atrophy (SMA) Drugs Players in Global Market
  3.6.1 List of Global Tier 1 Spinal Muscular Atrophy (SMA) Drugs Companies
  3.6.2 List of Global Tier 2 and Tier 3 Spinal Muscular Atrophy (SMA) Drugs Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Spinal Muscular Atrophy (SMA) Drugs Market Size Markets, 2021 & 2027
  4.1.2 Oral Medicine
  4.1.3 Injection Medicine
4.2 By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue & Forecasts
  4.2.1 By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2016-2021
  4.2.2 By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2022-2027
  4.2.3 By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Spinal Muscular Atrophy (SMA) Drugs Market Size, 2021 & 2027
  5.1.2 Baby
  5.1.3 Child
  5.1.4 Adult
5.2 By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue & Forecasts
  5.2.1 By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2016-2021
  5.2.2 By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2022-2027
  5.2.3 By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Spinal Muscular Atrophy (SMA) Drugs Market Size, 2021 & 2027
6.2 By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue & Forecasts
  6.2.1 By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2016-2021
  6.2.2 By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2022-2027
  6.2.3 By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Spinal Muscular Atrophy (SMA) Drugs Revenue, 2016-2027
  6.3.2 US Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.3.3 Canada Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.3.4 Mexico Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Spinal Muscular Atrophy (SMA) Drugs Revenue, 2016-2027
  6.4.2 Germany Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.4.3 France Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.4.4 U.K. Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.4.5 Italy Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.4.6 Russia Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.4.7 Nordic Countries Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.4.8 Benelux Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Spinal Muscular Atrophy (SMA) Drugs Revenue, 2016-2027
  6.5.2 China Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.5.3 Japan Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.5.4 South Korea Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.5.5 Southeast Asia Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.5.6 India Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Spinal Muscular Atrophy (SMA) Drugs Revenue, 2016-2027
  6.6.2 Brazil Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.6.3 Argentina Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue, 2016-2027
  6.7.2 Turkey Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.7.3 Israel Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.7.4 Saudi Arabia Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027
  6.7.5 UAE Spinal Muscular Atrophy (SMA) Drugs Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Biogen
  7.1.1 Biogen Corporate Summary
  7.1.2 Biogen Business Overview
  7.1.3 Biogen Spinal Muscular Atrophy (SMA) Drugs Major Product Offerings
  7.1.4 Biogen Spinal Muscular Atrophy (SMA) Drugs Revenue in Global (2016-2021)
  7.1.5 Biogen Key News
7.2 Novartis
  7.2.1 Novartis Corporate Summary
  7.2.2 Novartis Business Overview
  7.2.3 Novartis Spinal Muscular Atrophy (SMA) Drugs Major Product Offerings
  7.2.4 Novartis Spinal Muscular Atrophy (SMA) Drugs Revenue in Global (2016-2021)
  7.2.5 Novartis Key News
7.3 Genentech
  7.3.1 Genentech Corporate Summary
  7.3.2 Genentech Business Overview
  7.3.3 Genentech Spinal Muscular Atrophy (SMA) Drugs Major Product Offerings
  7.3.4 Genentech Spinal Muscular Atrophy (SMA) Drugs Revenue in Global (2016-2021)
  7.3.5 Genentech Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES

Table 1. Spinal Muscular Atrophy (SMA) Drugs Market Opportunities & Trends in Global Market
Table 2. Spinal Muscular Atrophy (SMA) Drugs Market Drivers in Global Market
Table 3. Spinal Muscular Atrophy (SMA) Drugs Market Restraints in Global Market
Table 4. Key Players of Spinal Muscular Atrophy (SMA) Drugs in Global Market
Table 5. Top Spinal Muscular Atrophy (SMA) Drugs Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Spinal Muscular Atrophy (SMA) Drugs Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Spinal Muscular Atrophy (SMA) Drugs Revenue Share by Companies, 2016-2021
Table 8. Global Companies Spinal Muscular Atrophy (SMA) Drugs Product Type
Table 9. List of Global Tier 1 Spinal Muscular Atrophy (SMA) Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Spinal Muscular Atrophy (SMA) Drugs Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Spinal Muscular Atrophy (SMA) Drugs Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Spinal Muscular Atrophy (SMA) Drugs Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Spinal Muscular Atrophy (SMA) Drugs Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Spinal Muscular Atrophy (SMA) Drugs Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2022-2027
Table 30. Biogen Corporate Summary
Table 31. Biogen Spinal Muscular Atrophy (SMA) Drugs Product Offerings
Table 32. Biogen Spinal Muscular Atrophy (SMA) Drugs Revenue (US$, Mn), (2016-2021)
Table 33. Novartis Corporate Summary
Table 34. Novartis Spinal Muscular Atrophy (SMA) Drugs Product Offerings
Table 35. Novartis Spinal Muscular Atrophy (SMA) Drugs Revenue (US$, Mn), (2016-2021)
Table 36. Genentech Corporate Summary
Table 37. Genentech Spinal Muscular Atrophy (SMA) Drugs Product Offerings
Table 38. Genentech Spinal Muscular Atrophy (SMA) Drugs Revenue (US$, Mn), (2016-2021)

LIST OF FIGURES

Figure 1. Spinal Muscular Atrophy (SMA) Drugs Segment by Type
Figure 2. Spinal Muscular Atrophy (SMA) Drugs Segment by Application
Figure 3. Global Spinal Muscular Atrophy (SMA) Drugs Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Spinal Muscular Atrophy (SMA) Drugs Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Spinal Muscular Atrophy (SMA) Drugs Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Spinal Muscular Atrophy (SMA) Drugs Revenue in 2020
Figure 8. By Type - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2016-2027
Figure 9. By Application - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2016-2027
Figure 10. By Region - Global Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2016-2027
Figure 11. By Country - North America Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2016-2027
Figure 12. US Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2016-2027
Figure 16. Germany Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 17. France Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2016-2027
Figure 24. China Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 28. India Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2016-2027
Figure 30. Brazil Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Spinal Muscular Atrophy (SMA) Drugs Revenue Market Share, 2016-2027
Figure 33. Turkey Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Spinal Muscular Atrophy (SMA) Drugs Revenue, (US$, Mn), 2016-2027
Figure 37. Biogen Spinal Muscular Atrophy (SMA) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Novartis Spinal Muscular Atrophy (SMA) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. Genentech Spinal Muscular Atrophy (SMA) Drugs Revenue Year Over Year Growth (US$, Mn) & (2016-2021)

More Publications

Need Help?

Ask a Question

Market Reports

All Categories